title: Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma.
abstract: Our aim was to assess the prognostic implications of the expression of p27(KIP1) and cyclin E in gastric lymphoma. We investigated the prognostic value of the immunoreactivity of these molecules in 92 cases of primary gastric lymphoma: 34 LGMLs, 24 DLCLMLs and 34 DLCLs. p27 was positive in 88% of LGMLs, 71% of DLCLMLs and 32% of DLCLs (p = 0.004); cyclin E was positive in 9%, 33% and 59% of cases, respectively (p < 0.00001). p27/cyclin E immunoreactivity significantly correlated with histologic category, stage and LDH serum level. p27 immunoreactivity was significantly associated with better survival, whereas cyclin E reactivity was significantly related to worse outcome. Five-year CSS was 94% for patients with p27(+)/cyclin E(-) phenotype (n = 42), 79% for p27(+)/cyclin E(+) (n = 14) or p27(-)/cyclin E(-) (n = 16) phenotype and 60% for p27(-)/cyclin E(+) phenotype (n = 16) (p = 0.02). The prognostic role of p27/cyclin E expression was confirmed when analyzed separately within LGMLs and large-cell lymphomas. Immunoreactivity for p27 and cyclin E is an independent predictor of survival in PGLs that may be an adjunctive tool in identifying high-risk patients. It correlates with histologic category, stage and LDH serum level. p27(-)/cyclin E(+) phenotype is associated with worse survival, probably due to a synergistic effect of both cell-cycle defects. The predictive role of these molecules within each histologic group of PGLs deserves to be confirmed in larger series.
authors.affiliation: Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy. andres.ferreri@hsr.it
authors.forename: A J
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: M
authors.initials: M
authors.lastname: Ponzoni
authors.forename: G
authors.initials: G
authors.lastname: Pruneri
authors.forename: M
authors.initials: M
authors.lastname: Freschi
authors.forename: R
authors.initials: R
authors.lastname: Rossi
authors.forename: S
authors.initials: S
authors.lastname: Dell'Oro
authors.forename: L
authors.initials: L
authors.lastname: Baldini
authors.forename: R
authors.initials: R
authors.lastname: Buffa
authors.forename: N
authors.initials: N
authors.lastname: Carboni
authors.forename: E
authors.initials: E
authors.lastname: Villa
authors.forename: G
authors.initials: G
authors.lastname: Viale
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018797:Cell Cycle Proteins / Q000096:biosynthesis / Q000276:immunology*; D002467:Cell Nucleus / Q000378:metabolism; D019927:Cyclin E / Q000096:biosynthesis / Q000276:immunology*; D050760:Cyclin-Dependent Kinase Inhibitor p27; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000276:immunology* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010641:Phenotype; D011379:Prognosis; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000401:mortality; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis / Q000276:immunology*
chemical_list: D018797:Cell Cycle Proteins; D019927:Cyclin E; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D007770:L-Lactate Dehydrogenase